natgillin/translations-raw huggingface dataset:
One serious adverse reaction of IRR was reported in a Crohn's disease patient during the second infusion (symptoms reported were dyspnoea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate) and was successfully managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. 
koprivnica, pordelost, izpuščaj in zvišan krvni tlak ter pospešen srčni utrip) in so ga uspešno obvladali s prekinitvijo infundiranja in z zdravljenjem z antihistaminikom in intravenskim hidrokortizonom.
(see Annex I: Summary of Product Characteristics, section 4.2). 
Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Week 6 Efficacy Results of GEMINI I 
Rezultati učinkovitosti v 6. tednu v študiji GEMINI I Opazovani dogodek
• pain in the limb 
• bolečina v žrelu,
*p < 0.05 †not statistically significant ‡secondary endpoint to be viewed as exploratory by pre-specified statistical testing procedure §not statistically significant, the other endpoints were therefore not tested statistically ¶n = 157 for placebo and n = 158 for vedolizumab #Sustained clinical remission: clinical remission at weeks 6 and 10 ^Exploratory Endpoint 
† ni statistično pomembno ‡ sekundarni opazovani dogodek, eksplorativno po vnaprej določenem statističnem postopku testiranja § ni statistično pomembno, drugi opazovani dogodki zato niso bili statistično obdelani
If you forget or miss your Entyvio infusion 
Če ste prenehali uporabljati zdravilo Entyvio
In these patients, clinical remission was achieved in 25% of patients at week 28 and week 52. 
Klinična remisija v 28. tednu in 52. tednu je bila dosežena pri 25 % teh bolnikov.
Sustained clinical remission#,¶ Overall 
Ohranitev klinične remisije#¶
Use aseptic technique when preparing Entyvio solution for intravenous infusion. 
Entyvio raztopino za intravensko infundiranje morate pripraviti v aseptičnih pogojih.
• throat and mouth yeast infection 
• glivična okužba žrela in ustne votline,
No vedolizumab clinical trial data are available for patients previously treated with natalizumab or rituximab. 
Pri bolnikih, ki so se predhodno zdravili z natalizumabom ali rituksimabom, podatki iz kliničnega preskušanja vedolizumaba niso na voljo.
Crohn's disease is an inflammatory disease of the gastrointestinal tract. 
Pri bolnikih z ulceroznim kolitisom in Crohnovo boleznijo vedolizumab zmanjša gastrointestinalno vnetje.
Age does not impact the vedolizumab clearance in ulcerative colitis and Crohn's disease patients based on the population pharmacokinetic analyses. 
Analize populacijske farmakokinetike kažejo, da pri bolnikih z ulceroznim kolitisom ali s Crohnovo boleznijo starost ne vpliva na očistek vedolizumaba.
trafficking into the CNS as evidenced by the lack of change in the ratio of CD4 +/CD8 
Vedolizumab ni vplival na cirkulacijo celic CD4+ in celic CD8+ v osrednje živčevje, kot je razvidno iz nespremenjenega razmerja CD4+/CD8+ v cerebrospinalni tekočini pred uporabo in po uporabi vedolizumaba pri zdravih prostovoljcih.
Very rare side effects (may affect up to 1 in 10,000 people) 
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): • pljučnica,
Bronchitis, Gastroenteritis, Upper respiratory tract infection, Influenza, Sinusitis, Pharyngitis 
Infekcijske in parazitske bolezni zelo pogosti nazofaringitis pogosti bronhitis, gastroenteritis, okužba zgornjih dihal, gripa, sinuzitis, faringitis občasni okužba dihal, kandidoza vulve in nožnice, kandidoza ustne sluznice, herpes zoster zelo redki pljučnica
TNFα Antagonist(s) Failure¶,‡ 
Neodziv na zaviralec (zaviralce) TNFα¶,‡
Very common Headache Common 
Bolezni živčevja zelo pogosti glavobol pogosti parestezija
TNFα Antagonist(s) Failure¶ 
Neodziv na zaviralec (zaviralce) TNFα
• pain at the infusion site 
• bolečina v okončini,
• chills or shivering 
• zbadanje ali mravljinčenje,
TNFα Antagonist(s) Naïve^ 
(zaviralci) TNFα^
• swelling 
• zgaga,
• rash and redness 
• izpuščaj in rdečina,
Concomitant stable doses of oral corticosteroids, immunomodulators, and antibiotics were permitted. 
Dovoljena je bila sočasna uporaba peroralnih kortikosteroidov,
GEMINI II contained two cohorts of patients that received vedolizumab at weeks 0 and 2: cohort 1 patients were randomised to receive either vedolizumab 300 mg or placebo in a double-blind fashion, and cohort 2 patients were treated with open-label vedolizumab 300 mg. To evaluate efficacy at week 52, 461 patients from cohorts 1 and 2, who were treated with vedolizumab and had achieved clinical response (defined as a ≥ 70-point decrease in CDAI score from baseline) at week 6, were randomised in a double-blind fashion (1:1:1) to one of the following regimens beginning at week 6: vedolizumab 300 mg every eight weeks, vedolizumab 300 mg every four weeks, or placebo every four weeks. 
≥ 70 točk od izhodišča), v 6. tednu randomizirani na dvojno slep način (1:1:1) na enega od naslednjih režimov, ki se je začel v 6. tednu: vedolizumab v odmerku 300 mg na vsakih osem tednov, vedolizumab v odmerku 300 mg na vsake štiri tedne ali placebo na vsake štiri tedne.
Powder for concentrate for solution for infusion in Type 1 glass vial (20 mL) fitted with rubber stopper and aluminium crimp protected by a plastic cap. 
6.5 Vrsta ovojnine in vsebina Prašek za koncentrat za raztopino za infundiranje je na voljo v 20 ml stekleni viali (steklo tipa 1),
• heart burn 
• glavobol.
Oropharyngeal pain, Nasal congestion, Cough 
Bolezni dihal, prsnega koša in mediastinalnega prostora pogosti bolečina v ustih in žrelu, kongestija nosne sluznice, kašelj
Fre que ncy 
(zaviralci) TNFα
• muscle weakness 
• oslabelost mišic,
Respiratory, thoracic and mediastinal disorders 
razredčena raztopina z natrijevim kloridom
It is to be reconstituted and further diluted prior to intravenous administration 
Pred intravenskim infundiranjem je treba zdravilo rekonstituirati in nadalje razredčiti.
Inspect the reconstituted solution visually for particulate matter and discolouration prior to dilution. 
Po rekonstituciji in pred redčenjem raztopino preglejte glede morebitne prisotnosti trdnih delcev in spremembe barve.
Population pharmacokinetic analyses indicate that vedolizumab has a total body clearance of approximately 0.157 L/day and a serum half-life of 25 days. 
0,157 l/dan, razpolovni čas v serumu pa 25 dni.
Clinical remission 
Ponovna uvedba zdravljenja
Musculoskeletal and connective tissue disorders 
Razredčena raztopina z natrijevim kloridom
• chest infection 
• okužba v prsnem košu,
• throat pain 
• trdo blato,
The combined in-use stability of Entyvio in the vial and infusion bag with sodium chloride 9 mg/mL (0.9%) solution for injection is a total of 12 hours at 20°C-25°C or 24 hours at 2°C-8°C. 
(0,9 %) raztopino za injiciranje, je skupno 12 ur pri temperaturi 20 °C-25 °C ali 24 ur pri temperaturi 2 °C-8 °C.
2 This time assumes the reconstituted solution is immediately diluted in the sodium chloride 9 mg/mL (0.9%) solution for injection and held in the infusion bag only. 
5 ml (300 mg) rekonstituirane raztopine zdravila Entyvio dodajte v 250 ml sterilne raztopine za injiciranje natrijevega klorida 9 mg/ml (0,9 %) in vsebino infuzijske vrečke nežno premešajte
Clinical response Clinical remission§ Mucosal healing¶ 
Klinični odziv Klinična remisija§
TNFα Antagonist(s) Naïve 
Crohnova bole ze n
Exploratory analysis showed clinically meaningful improvements were observed for the vedolizumab every four weeks and every eight weeks groups in GEMINI II and the improvements were significantly greater as compared with the placebo group from baseline to week 52 on EQ-5D and EQ-5D VAS scores, total IBDQ score, and IBDQ subscales of bowel symptoms and systemic function. 
Eksplorativna analiza je pokazala klinično pomembno izboljšanje pri uporabi vedolizumaba na vsake štiri tedne in na vsakih osem tednov v študiji GEMINI II.
World Health Organization. 
1Svetovna zdravstvena organizacija.
The CHMP concluded 
je CHMP sklenil
Available on http://www.who.int/wer/2011/wer8629.pdf 29(86) Ref Type: Internet Communication 
Dostopno na http://www.who.int/wer/2011/wer8629.pdf
There is an estimated theoretical risk of severe malformations attributed to the rubella containing vaccine that varies between 0.5% and 1.3%. 
Ocenjeno teoretično tveganje hudih okvar, ki jih je mogoče pripisati cepivu, ki vsebuje virus rdečk, znaša od 0,5 % do 1,3 %.
Based on the above, Belgium national competent authorities triggered a referral under Article 31 of Directive 2001/83/EC on 9 March 2012, requesting the CHMP to review the benefit/risk of these vaccines in the above mentioned populations, i.e. pregnant women and subjects with immune deficiencies. 
Na podlagi zgoraj navedenega so belgijski nacionalni pristojni organi 9. marca 2012 sprožili napotitveni postopek na podlagi člena 31 Direktive 2001/83/ES, v katerem CHMP naproša za ponovno presojo razmerja med tveganji in koristmi teh cepiv pri zgoraj omenjenih populacijah, tj. nosečnicah in osebah z imunskimi pomanjkljivostmi.
Immunocompromised subjects 
Osebe z oslabljenim imunskim sistemom
Grounds for variation to the terms of the marketing authorisations 
Razlogi za spremembo pogojev dovoljenj za promet z zdravilom
The CHMP acknowledged that MMRV vaccines should remain contraindicated in patients with severely impaired humoral and/or cellular immune systems such as severe combined immunodeficiency (SCID) and agammaglobulinemia. 
CHMP je potrdil, da morajo cepiva MMRV ostati kontraindicirana pri bolnikih s hudo oslabljenim humoralnim in/ali celičnim imunskim sistemom, kot sta huda kombinirana imunska pomanjkljivost in agamaglobulinemija.
However, it was noted by the CHMP that the data from post-marketing surveillance and pregnancy registry were limited due to the current contraindication in the product information and were too poorly documented to draw any conclusion. 
Vendar je CHMP ugotovil, da je podatkov iz postopka spremljanja v obdobju trženja in nosečniškega registra premalo zaradi trenutne kontraindikacije v informacijah o zdravilu in da so ti preslabo dokumentirani za postavitev kakršnega koli sklepa.
• that vaccination with MMRV vaccines may be considered in patients with selected immune deficiencies when the benefit outweighs the risk of vaccination. 
• da je o cepljenju s cepivi MMRV možno razmisliti pri bolnikih z nekaterimi oblikami imunske pomanjkljivosti, kadar je korist teh cepiv večja od tveganja pri cepljenju.
Moreover, a warning should be added as vaccination may be considered in patients with selected immune deficiencies (e.g. IgG subclass deficiencies, congenital neutropenia, chronic granulomatous disease, and complement deficiency diseases), if the benefit outweighs the risk of vaccination. 
Poleg tega je treba dodati opozorilo, da je cepivo mogoče uporabiti pri bolnikih z nekaterimi oblikami imunske pomanjkljivosti (npr. pomanjkljivostmi podrazreda IgG, prirojeno nevtropenijo, kronično granulomatozno boleznijo in pomanjkljivostmi komplementa), če so koristi cepljenja večje od z njim povezanih tveganj.
Having considered all available data, the CHMP is of the opinion that MMRV vaccination should continue to be contraindicated in pregnant women. 
Ob upoštevanju vseh razpoložljivih podatkov je CHMP bil mnenja, da mora ostati cepljenje proti MMVR še naprej kontraindicirano pri nosečnicah.
Annex II Scientific conclusions and grounds for variation to the terms of the Marketing Authorisations 
Znanstveni zaključki in podlaga za spremembo pogojev dovoljenj za promet z zdravilom
Monovalent and multivalent measles, mumps, rubella and/or varicella containing vaccines (MMRV) are live attenuated vaccines which are indicated in vaccination of adults and children against these viruses. 
Eno- in večvalentna cepiva, ki vsebujejo viruse ošpic, mumpsa, rdečk in/ali noric (MMRV), so živa oslabljena cepiva, indicirana za cepljenje odraslih in otrok proti tem virusom.
On the basis of the most recent published data on rubella containing vaccines, in particular for pregnant women Belgium national competent authorities considered it was justified to review whether monovalent and multivalent MMRV vaccines should remain contraindicated in pregnant women as vaccination in some individual cases may outweigh the risk. 
Na podlagi najnovejših objavljenih podatkov o cepivih, ki vsebujejo virus rdečk, so belgijski nacionalni pristojni organi sklenili, da je zlasti pri nosečnicah upravičeno pregledati, ali naj eno- in večvalentna cepiva MMRV ostanejo kontraindicirana pri nosečnicah, saj so lahko koristi cepljenja v nekaterih posameznih primerih večje od z njim povezanih tveganj.
Taking into account that rubella and varicella vaccination induce a fast immune response that make post-exposure prophylaxis possible, based on available evidence and as reflected in WHO recommendation, the CHMP considered that there are sufficient data to reduce the period post-vaccination where pregnancy should be avoided. 
Ker cepljenje proti rdečkam in noricam izzove hiter imunski odziv, ki omogoča zaščito po izpostavitvi, je CHMP na podlagi razpoložljivih dokazov in priporočil SZO menil, da podatki zadoščajo za skrajšanje obdobja po cepljenju, v katerem naj ženske ne zanosijo.
• that the data were sufficient to amend the product information to mention that pregnancy should be avoided for 1 month (instead of 3 months) following vaccination. 
• da podatki zadoščajo, da se informacije o zdravilu spremenijo in se obdobje, v katerem naj ženske po cepljenju ne zanosijo, skrajša na 1 mesec (namesto 3 mesecev).
However, the CHMP concluded that the current contraindication for use of MMRV vaccines in immunocompromised subjects should be amended to clarify that, according to WHO guidelines and scientific data, for HIV-infected patients age specific %CD4+ is to be included. 
Vendar pa je CHMP zaključil, da je treba trenutno kontraindikacijo za uporabo cepiv MMRV pri bolnikih z oslabljenim imunskim sistemom spremeniti tako, da se skladno s smernicami SZO in znanstvenimi podatki za bolnike, okužene z virusom HIV, vključi starostno specifični odstotek CD4+.
The CHMP considered that the contraindication should be harmonised and adjusted according to WHO guidance and scientific data and that although these vaccines are generally contraindicated in immunocompromised subjects, some individuals may benefit from vaccination. 
CHMP je menil, da je treba kontraindikacijo uskladiti in prilagoditi v skladu s smernicami SZO in znanstvenimi podatki ter da lahko cepljenje koristi nekaterim posameznikom, čeprav so ta cepiva navadno kontraindicirana pri osebah z oslabljenim imunskim sistemom.
• the CHMP considered the referral under Article 31 of Directive 2001/83/EC for monovalent and multivalent measles, mumps, rubella and varicella containing vaccines. 
• CHMP je obravnaval napotitveni postopek iz člena 31 Direktive 2001/83/ES za eno- in večvalentna cepiva, ki vsebujejo viruse ošpic, mumpsa, rdečk in noric;
• that the data provided were too limited and poorly documented to draw any conclusion and therefore without any sufficient data monovalent and multivalent MMRV vaccines should remain contraindicated during pregnancy. 
• da je podatkov premalo in da so ti preslabo dokumentirani, da bi omogočali sklepe, zato morajo eno- in večvalentna cepiva proti MMRV zaradi odsotnosti zadostnih podatkov ostati kontraindicirana med nosečnostjo;
• the CHMP reviewed all available data regarding use in pregnant women and in immunocompromised patients of rubella containing vaccines, including the most recent publications and data from post-marketing surveillance for monovalent and multivalent measles, mumps, rubella and varicella vaccines. 
• CHMP je pregledal vse razpoložljive podatke o uporabi cepiv, ki vsebujejo virus rdečk, pri nosečnicah in bolnikih z oslabljenim imunskim sistemom, vključno z najnovejšimi publikacijami in podatki iz postopka spremljanja v obdobju trženja za eno- in večvalentna cepiva proti ošpicam, mumpsu, rdečkam in noricam;
When considering the data from studies in the literature and the data from post-marketing surveillance the CHMP concluded that although a theoretical risk cannot be excluded, no case of CRS has been reported in more than 3500 susceptible women who were unknowingly in early stages of pregnancy when vaccinated against rubella. 
Ko je CHMP obravnaval podatke iz študij v literaturi in podatke iz postopka spremljanja v obdobju trženja, je ugotovil, da kljub temu, da ni mogoče izključiti teoretičnega tveganja, pri več kot 3 500 dovzetnih ženskah, ki so bile cepljene proti rdečkam v zgodnji nosečnosti, ko za nosečnost še niso vedele, niso poročali o nobenem primeru sindroma prirojenih rdečk.
For completeness, the CHMP also recommended the update of the product information to reflect the most recent published data regarding vaccination against rubella in pregnant women. 
Zaradi celovitosti je CHMP priporočil tudi dopolnitev informacij o zdravilu z najnovejšimi objavljenimi podatki glede cepljenja nosečnic proti rdečkam.
Overall summary of the scientific evaluation of the measles, mumps, rubella and varicella containing vaccines (see Annex I) 
Splošni povzetek znanstvenega vrednotenja cepiv, ki vsebujejo viruse ošpic, mumpsa, rdečk in noric (glejte Prilogo I)
Regarding the contraindication on immunocompromised subjects, an assessment of the safety of MMRV vaccines (based on experience to date) in subjects with various types of immune deficiencies (e.g. T-cell defects, sub-class deficiencies etc.) was provided by the Marketing Authorisation Holders (MAHs). 
Glede kontraindikacije pri osebah z oslabljenim imunskim sistemom so imetniki dovoljenj za promet z zdravilom predložili oceno varnosti cepiv MMRV (ki temelji na dosedanjih izkušnjah) pri osebah z različnimi vrstami imunske pomanjkljivosti (npr. okvarami limfocitov T, pomanjkljivostmi podrazreda).
Therefore, the CHMP recommended the variation to the terms of the marketing authorisations for which the relevant sections of the summaries of product characteristics and package leaflets are set out in Annex III for monovalent and multivalent measles, mumps, rubella and varicella containing vaccines (see Annex I). 
CHMP je posledično priporočil spremembo pogojev dovoljenj za promet z zdravilom, za katera so zadevna poglavja povzetka glavnih značilnosti zdravila in navodila za uporabo za eno- in večvalentna cepiva, ki vsebujejo viruse ošpic, mumpsa, rdečk ter noric (glejte Prilogo I), določena v Prilogi III.
The CHMP also considered that the most recent published data regarding vaccination against rubella in pregnant women should be reflected in the summary of product characteristics of the monovalent rubella vaccines and multivalent MMR vaccines. 
CHMP je prav tako menil, da je treba najnovejše podatke o cepljenju proti rdečkam pri nosečnicah vključiti v povzetek glavnih značilnosti zdravila za enovalentna cepiva proti rdečkam in večvalentna cepiva MMR;
In addition, published data also indicated that some groups of individuals other than pregnant women could benefit from a MMRV vaccine and therefore the contraindication for immunocompromised subjects needed to be reviewed. 
Objavljeni podatki kažejo tudi,da bi lahko cepivo MMRV razen nosečnicam koristilo tudi drugim skupinam posameznikov, zato je bilo treba ponovno presoditi o kontraindikaciji pri osebah z oslabljenim imunskim sistemom.
Based on the low theoretical teratogenic risk and the fact that no case of CRS has been reported, it should also be mentioned in the SmPC that inadvertent vaccination of unknowingly pregnant women with monovalent or multivalent mumps, measles and rubella containing vaccines should not be a reason for termination of pregnancy. 
Glede na majhno teoretično teratogeno tveganje in odsotnost poročil o primerih sindroma prirojenih rdečk je treba v povzetku glavnih značilnosti zdravila navesti tudi, da nenamerno cepljenje žensk, ki ne vedo, da so noseče, z eno- ali večvalentnimi cepivi, ki vsebujejo viruse mumpsa, ošpic in rdečk, ni razlog za prekinitev nosečnosti.
Vaccination with these MMRV vaccines is contraindicated in pregnant women and in immunocompromised subjects. 
Uporaba cepiv MMRV je kontraindicirana pri nosečnicah in osebah z oslabljenim imunskim sistemom.
The contraindication in this patient population was also further defined by inclusion of age specific %CD4+ for HIV-infected patients. 
Z vključitvijo starostno specifičnega odstotka CD4+ za bolnike, okužene z virusom HIV, je bila podrobneje opredeljena tudi kontraindikacija pri tej populaciji bolnikov;
The product information is therefore amended accordingly to reflect that pregnancy should be avoided for 1 month following vaccination instead of 3 months. 
Informacije o zdravilu so bile zato spremenjene tako, da se obdobje po cepljenju, v katerem naj ženske ne zanosijo, skrajša s 3 mesecev na 1 mesec.
Evidence from post marketing surveillance and published literature that focused on risk of spontaneous abortion, miscarriage, stillbirth, immaturity and low birth weight in women susceptible to measles, mumps, rubella and/or varicella, risk of malformation and congenital rubella syndrome (CRS) in offspring of such women, and risk of congenital varicella syndrome (CVS) were considered for the review of the contraindication on pregnancy. 
Pri ponovni presoji kontraindikacije med nosečnostjo so bili uporabljeni dokazi iz postopka spremljanja v obdobju trženja in objavljene literature, ki zadevajo tveganja spontanega splava, abortusa, mrtvorojenega otroka, nedonošenosti ali nizke porodne teže pri ženskah, dovzetnih za ošpice, mumps, rdečke in/ali norice, tveganje okvar in sindrom prirojenih rdečk pri potomcih teh žensk ter sindrom prirojenih noric.
Data provided from post marketing surveillance and published literature did not show any safety concern with respect to spontaneous abortion or congenital malformations in pregnant women that were inadvertently vaccinated with MMRV vaccines and no case of CRS or CVS have been reported. 
Podatki iz postopka spremljanja v obdobju trženja in objavljene literature niso pokazali nobenih varnostnih zadržkov, povezanih s spontanim splavom ali prirojenimi okvarami pri nosečnicah, ki so bile nenamerno cepljene s cepivi MMRV, poleg tega tudi niso poročali o primerih sindroma prirojenih rdečk ali sindroma prirojenih noric.
Because of this theoretical teratogenic risk, the World Health Organization (WHO) recommended in 2011 that vaccination against rubella should be avoided in principle in pregnant women and women who intend to become pregnant should be advised to delay for 1 month following rubella vaccination1. 
Zaradi tega teoretičnega teratogenega tveganja je Svetovna zdravstvena organizacija (SZO) leta 2011 priporočila, da se je treba cepljenju nosečnic proti rdečkam načeloma izogibati, ženskam, ki načrtujejo zanositev, pa je treba svetovati, da še 1 mesec po cepljenju proti rdečkam ne zanosijo.1 Trenutni podatki kažejo, da so ravni IgM proti rdečkam najvišje približno 30 dni po cepljenju, prav tako pa je mogoče zaznati IgG.
However, we want to take this a step forward. 
Vendar pa želimo iti korak naprej.
The Agency will concentrate its efforts in three areas: 
Agencija bo svoja prizadevanja osredotočila na tri področja:
The implementation of Article 5(3) and Article 107(2) procedures which are new legal provisions will be monitored carefully. 
Izvajanje postopkov po členih 5(3) in 107(2), ki so nove pravne določbe, se bo skrbno spremljalo.
These systems are evolving in line with communicated requirements. 
Ti sistemi se razvijajo skladno s sporočenimi zahtevami.
This will result from routine maintenance activities. 
To bo rezultat rutinskih vzdrževalnih dejavnosti.
The implementation strategy concentrates on a number of projects with high European added value. 
Izvajanje strategije je osredotočeno na nekaj projektov z visoko evropsko dodano vrednostjo.
Work on the next version will be postponed to 2009. 
Delo na naslednji različici bo preloženo v leto 2009.
1.6 Preparations for future enlargement 
1.6 Priprave na prihodnjo širitev
Additional priorities in 2007 will include: 
Dodatne prednostne naloge v letu 2007 bodo vključevale:
The priorities and key objectives for 2007 can be summarised as follows: 
Prednostne naloge in ključne cilje za leto 2007 je mogoče povzeti na naslednji način: